Kintor Pharmaceutical Limited
KNTPF
$0.3643
$0.034910.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 696.70K | 349.20K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 696.70K | 349.20K | -- | -- | -- |
| Cost of Revenue | 435.60K | -145.40K | -727.00K | -649.10K | -570.50K |
| Gross Profit | 261.20K | 494.70K | 727.00K | 649.10K | 570.50K |
| SG&A Expenses | 12.46M | 11.22M | 9.95M | 11.76M | 13.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.78M | -1.54M | -288.90K | -680.90K | -1.09M |
| Total Operating Expenses | 20.98M | 71.32M | 121.46M | 131.99M | 142.84M |
| Operating Income | -20.28M | -70.97M | -121.46M | -131.99M | -142.84M |
| Income Before Tax | -21.59M | -75.06M | -128.32M | -138.55M | -149.11M |
| Income Tax Expenses | 2.50K | -519.20K | -1.04M | -1.08M | -1.12M |
| Earnings from Continuing Operations | -21.59 | -74.54 | -127.28 | -137.48 | -148.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.59M | -74.54M | -127.28M | -137.48M | -148.00M |
| EBIT | -20.28M | -70.97M | -121.46M | -131.99M | -142.84M |
| EBITDA | -18.46M | -69.16M | -119.67M | -130.11M | -140.88M |
| EPS Basic | -0.05 | -0.17 | -0.30 | -0.32 | -0.34 |
| Normalized Basic EPS | -0.03 | -0.10 | -0.18 | -0.19 | -0.21 |
| EPS Diluted | -0.05 | -0.17 | -0.30 | -0.32 | -0.34 |
| Normalized Diluted EPS | -0.03 | -0.10 | -0.18 | -0.19 | -0.21 |
| Average Basic Shares Outstanding | 1.72B | 1.72B | 1.72B | 1.72B | 1.72B |
| Average Diluted Shares Outstanding | 1.72B | 1.72B | 1.72B | 1.72B | 1.72B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |